Avai Bio 10-Q: Going Concern Doubt, $4.35M Working Capital Deficit, $10M Raise Needed
AVAI is trading near its 52-week low of $0.07 (7.1% above the low) on light trading volume (0.1× avg).
Summary
Avai Bio's September-quarter 10-Q shows no revenue, $121,948 of cash, a $4.35M working capital deficit and renewed going-concern doubt, with management saying it needs roughly $10M of new capital.
Key Events · Earnings and Guidance · AVAI
-
Going Concern Doubt Reaffirmed
Citing recurring losses, the company reports 'substantial doubt about the Company's ability to continue as a going concern,' dependent on raising additional investment capital.
-
Cash Burn Outpaces Thin Cash Balance
Net cash used in operating activities was $489,577 for the six months ended September 30, 2026, against a cash balance of just $121,948.
-
Working Capital Deficit Widens
Working capital deficit grew to $4,346,839 from $3,298,511 at March 31, 2026, and stockholders' deficit widened to $3,415,806 from $2,815,155.
-
Company Says It Needs ~$10M
Management states that to fully implement its business plan 'we will need to raise about $10,000,000,' which would mean further equity or convertible debt issuance.
Analysis · AVAI · Technology
The funding gap is the whole story for this $0.075 OTC stock. Avai Bio still has no revenue and burned $489,577 of cash on operations in the six months to September 30, 2026, leaving $121,948 of cash against a working capital deficit of $4,346,839. Management repeats that there is substantial doubt about the company's ability to continue as a going concern and says it needs to raise about $10,000,000 to fully implement its business plan — money that would almost certainly come from more share issuance, on top of the 154.4M shares already outstanding. The loss narrowed to $805,281 from $940,605 on lower marketing and G&A spend, but the balance sheet got weaker, not stronger: stockholders' deficit widened to $3,415,806 and management concluded its disclosure controls and procedures were not effective.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVAI was trading at $0.08 on OTC in the Technology sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $0.07 to $0.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.